TITLE: KEY ELEMENTS IN HYPERSENSITIVITY REACTIONS TO CHEMOTHERAPY: EXPERIENCE WITH RAPID DRUG DESENSITIZATION IN GYNAECOLOGICAL CANCER IN A TERTIARY HOSPITAL

AUTHORS:

Iolanda Alen Coutinho^{1,*}, Filipa Costa Sousa^{2,3,*}, Francisca Cunha¹, Cristina Frutuoso⁴, Carmelita Ribeiro¹, Carlos Loureiro¹, Fernanda Águas², Ana Todo Bom^{1,4}

* - contributed equally

AFFILIATIONS:

1. Allergy and Clinical Immunology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal
2. Gynecology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal
3. Coimbra Clinical Academic Center, Faculty of Medicine, University of Coimbra, Coimbra, Portugal
4. Institute of Pathophysiology, Faculty of Medicine, University of Coimbra, Coimbra, Portugal

The work was conducted at Allergy and Clinical Immunology and Gynecology Departments at Centro Hospitalar e Universitário de Coimbra Coimbra, Portugal.

CORRESPONDING AUTHOR

Iolanda Alen Coutinho

Address: Serviço de Imunoalergologia, Centro Hospitalar Universitário de Coimbra, Praceta Prof. Mota Pinto, 3000-075 Coimbra, Portugal

Phone number: 00 351 96 322 33 25; Email address: iolandaalen@gmail.com

ABSTRACT

Rapid drug desensitization (RDD) is a procedure performed when no alternative drug is considered equally effective. The aim of our study is to describe the experience with RDD to cytostatics in patients being treated for gynaecological cancer in a tertiary hospital, over a period of 5 years. In this paper, we review 22 cases and 107 episodes of RDD; 86.3% of patients had advanced disease and the mortality rate at the time of data collection was 50.0%. RDD was performed on 81.3% patients for platinum, 13.6% for taxanes, and 4.5% for anthracyclines. The reintroduction of antineoplastic drugs in all patients with a previous history of immediate hypersensitivity reaction demonstrated the safety and efficacy of this procedure. There was serious complication (anaphylaxis) in only one case.

KEY WORDS

Adults; chemotherapy hypersensitivity reactions; gynaecological cancer; rapid desensitization; risk factors.

LIST OF ABBREVIATIONS

AJCC – American Joint Committee on Cancer;

BGS – Brown's grading system;

BRCA – Breast Cancer gene;

DNA – Deoxyribonucleic acid;

EAACI – European Academy of Allergy and Clinical Immunology;

FDA – United States Food and Drug Administration;

FIGO – The International Federation of Gynecology and Obstetrics;

HER2 – Epidermal growth factor receptor 2;

HCR – Hypersensitivity reactions;

IgE – Immunoglobulin E;

IDs – Intradermal tests;

Kg – kilogram;

mg – Milligram;

μl – Microliter;

mL – Millimeter;

m² – square meter;

N/A – not applicable;

NOS – not otherwise specified;

PLD – Pegylated liposomal doxorubicin;

RDD – Rapid drug desensitization;

RNA – Ribonucleic acid;

SPT – Skin prick tests;

TNM – Tumour (T), nodes (N), metastases (M);

VUS – Variant of unknown significance;

WHO – World Health Organization.

INTRODUCTION

Considering developed countries, the most lethal gynaecological cancer is ovarian, especially high-grade serous carcinoma¹. Ovarian cancer is usually diagnosed at advanced stages (stage III and IV of The International Federation of Gynecology and Obstetrics – FIGO)^{1,2}, with 5-year survival rates in all stages reported as low as 50%³. Platinum-based therapeutic agents are widely used in this subtype, due to a generally good response¹. Other histological types like low-grade serous or clear cell ovarian carcinomas do not show such a good clinical response to these therapies¹, but can still be used in these cases. Platinum sensitivity is described as an absence of relapse for at least 6 months after the last cycle of chemotherapy⁴. Nevertheless, platinum agents also play an important role in subsequent relapses of ovarian cancer, as sensitivity is often retained⁴. Paclitaxel is often used together with platinum drugs, as this combination improves overall survival in patients with recurrent platinum-sensitive ovarian cancer⁵. Platinum-related hypersensitivity reactions (HSR) are reported at a rate of 1 in 10 patients, with higher incidence in advanced stages of the disease (stages III-IV), with serous carcinoma subtype and in the presence of ascites⁵. Multiple cycles of platinum therapies increase the probability of an HSR^{4,5}, so desensitization protocols can enhance the chance of retreatment with these drugs and thus increase patient survival.

In developed countries, endometrial cancer is the most common non gynaecological malignancy⁶. Most of these tumours have a postmenopausal diagnosis and are usually detected at stage I (with > 95% survival rates at 5 years), although they can appear before 40 years of age^{6,7}. Nevertheless, if there is locoregional advanced or distant disease, survival rates decrease markedly⁸. There are no population-based screening programmes for endometrial or ovarian cancer. Among those with high-risk factors for endometrial tumours, only those with Lynch syndrome have customized screening programmes.

Three of the main histological endometrial cancer subtypes according to the World Health Organization (WHO) include endometrioid, serous, and clear-cell carcinomas⁹. Classically and biologically, endometrial carcinomas are divided into 2 types, with type 2 referring to those with typically worse prognosis and including high-grade carcinomas^{7,9}.

FIGO classification is used for staging endometrial tumours; the staging is surgical¹⁰. Additionally, a risk group stratification classifies the following cases as a high-risk disease: endometrioid IB G3; stage $\geq$ II; and non-endometrioid histological subtype¹¹. Chemotherapy is recommended in endometrioid stage III of FIGO and the approved regime is carboplatin plus paclitaxel. The same therapy is proposed for serous and clear-cell carcinomas^{12,13}.

Worldwide, breast cancer is the main cause of cancer-related deaths in women¹⁴. The incidence of breast cancer increases with age (only 25% of cases occur before age 50) and has increased due to the application of national screening programmes with the use of mammography¹⁴. As increasing numbers

of breast cancer cases are diagnosed at an earlier stage, the mortality rate has decreased in developed countries in recent years¹⁴. The histological diagnosis is based on WHO classification and the eighth edition of the American Joint Committee on Cancer (AJCC) tumour, node, metastases (TNM) staging system. These include biological prognostic information: grade, hormonal receptors, human epidermal growth factor receptor 2 (HER 2) and possibly gene expression¹⁴. Of all the breast cancer subtypes, invasive carcinomas not otherwise specified (NOS) are the most frequent¹⁴.

Hypersensitivity reactions to chemotherapeutic agents

HSRs to a chemotherapy agent are defined as unexpected reactions that cannot be explained by the known toxicity profile of the drug¹⁵. Based on their development mechanism, HSRs are classified as allergic, which involves an immunological mechanism, and non-allergic, when an immunological pathogenic mechanism is not demonstrated¹⁶. The type of allergic reaction is classified into four categories based on the *Gell and Coombs* classification: type I immunoglobulin E (IgE)-mediated or immediate type; type II cytotoxic-mediated; type III immune complex-mediated; and type IV T cell-mediated or delayed type¹⁷.

Current data indicate that most patients who have experienced HSRs within 24 hours of the last drug administration achieve drug-tolerance with rapid desensitization¹⁶. Immediate drug HSRs usually occur within 1–6 h after the last administration of the drug, and can be IgE-mediated or related to a non-specific histamine release. Non-immediate or delayed reactions can occur at any time from 1 h after the initial drug administration, typically up to 6–12 h. Specifically in cases of chemotherapy, HSRs can occur more than 24 h after drug infusion, probably due to its prolonged half-life, or the administration of premedication drugs, which can mask the acute phase of these reactions.^{18,19,20}

Platinum compounds

Platinum compounds, such as cisplatin, carboplatin and oxaliplatin, are useful antineoplastic agents used in a wide variety of cancers, particularly in gynaecological malignancies^{21,22,23}. The first platinum drug approved by the United States Food and Drug Administration (FDA) as an anticancer agent was cisplatin in 1979, with carboplatin being approved almost twenty years later in 1989¹⁷. These chemotherapy agents are classified as deoxyribonucleic acid (DNA) alkylating agents. However, cisplatin was gradually replaced by carboplatin in patients with ovarian cancer, due to its reduced nephrotoxicity, neurotoxicity and gastrointestinal toxicity^{24,25}. Oxaliplatin is a third-generation platinum agent that, similarly to cisplatin and carboplatin, consists of a DNA alkylating agent that forms intrastrand/interstrand DNA crosslinks, affecting DNA base pairing, replication, gene transcription, and cell death^{26,27}. The mechanism by which platinum compounds cause HSRs remains

unclear, but they are generally reported as being IgE-mediated reactions^{17,25,28}. In the available studies regarding the incidence of HSRs to platinum compounds: cisplatin HSRs range from 1% to 20%; carboplatin HSRs increase with the number of cycles, and range from 1% in those that received ≤ 6 cycles to 27% in those who received ≥ 7 cycles, and up to 47% in those who received ≥ 15 cycles; and oxaliplatin HSRs range from 10% to 25%^{27,29,30,31}. The incidence of cross-reactivity between platinum agents has yet to be clarified, but some studies have documented the cross-reactivity between carboplatin and cisplatin as being higher than 25%³². The clinical manifestations of HSRs are diverse and unpredictable, varying from only cutaneous manifestations to severe or even fatal manifestations^{27,33}.

Taxanes

Similar to platinum compounds, taxanes are an important cause of HSRs in oncologic patients. The most used taxanes are paclitaxel and docetaxel. Paclitaxel is a natural compound, originally isolated from the bark of the Pacific yew tree, with its antineoplastic effect interfering with the dynamics of microtubules (cytoskeleton), causing mitotic block and cell death^{34,35,36}. Docetaxel is a semi-synthetic molecule derived by a taxoid precursor found in European yew trees³⁶. Due to their low solubility, they are formulated with solvents to allow intravenous administration: Cremophor® EL is associated with paclitaxel and polysorbate 80 with docetaxel³⁴. These solvents are capable of causing complement activation which leads to anaphylatoxins production and mast cell activation, thereby explaining why some patients experience immediate HSPs³³. Initial studies with taxanes revealed a high incidence of immediate HSRs, which led to the use of premedication with antihistamine and corticosteroids³⁷. Currently, immediate HSRs to paclitaxel and docetaxel occur in about 10% and 5% of premedicated patients, respectively³⁷. Immediate HSRs to taxanes occur minutes after starting the infusion during the first or second cycles, and symptoms include flushing, chest, back and abdominal pain, as well as respiratory symptoms^{34,36}. Cross-reactivity between paclitaxel and docetaxel exists but seems to vary among different populations and depends on the severity of the initial HSR³³.

Anthracyclines

Anthracyclines, such as doxorubicin, idarubicin, daunorubicin and epirubicin, are used to treat multiple malignancies, interfering with DNA metabolism and ribonucleic acid (RNA) production. HSRs to anthracyclines are rare³³. Clinically, the most important anthracycline that has been well studied, particularly in gynaecological malignancies, is pegylated liposomal doxorubicin (PLD)³³. The reported incidence of immediate HSRs to PLD is 9%¹⁷. This is similar to the incidence of HSRs to taxanes and usually occurs at an interval of 5 minutes after the first cycle, with flushing, back pain and chest

tightness as clinical manifestations¹⁷. The mechanism of HSRs is not clear, but it is believed that symptoms derive from complement and mast cell activation³⁸. Also, interestingly, the free form of doxorubicin does not cause HSRs, with pegylated liposomes being the probable trigger for these reactions³⁸.

Risk factors to hypersensitivity reactions in chemotherapeutic agents

The main risk factor influencing the occurrence of platinum HSRs is the total number of cycles that patients have received, with the peak of HSRs usually occurring during the 8th or 5th cycle³³. Similarly, other risk factors have been reported, namely a history of atopy and drug allergy, a long platinum-free interval and the administration of ≥ 650 mg of carboplatin³³. The inherited mutations in breast cancer type 1 or 2 genes (BRCA 1 or 2) appear to be related to a higher risk of reactions to carboplatin infusion and patients are also at risk for these reactions during desensitization²⁴. On the other hand, the combination of carboplatin with PLD seems to reduce the incidence of HSRs when compared to the administration of isolated carboplatin or its combination with paclitaxel²⁷. There are studies suggesting that the combination of specific chemotherapeutic drugs may have a predictive value on the HSRs risk^{27,39}. Joly *et al* suggested that the use of carboplatin associated with pegylated liposomal doxorubicin presented a low rate of HSRs, when compared to the combination with paclitaxel, which seems to be associated with a higher number of HSRs, probably due to potentiation secondary to paclitaxel co-administration^{27,39}. The predictive factors for HSRs in the case of taxanes remain unclear. However, one study identified that younger age, previous allergy history and a short-course of premedication were associated with paclitaxel HSRs.⁴⁰ Other comorbidities, such as obesity (body mass index > 30 kg / m²) have also been associated with an increased risk of HSR to chemotherapy agents⁴¹.

The influence of the presence of eosinophils in allergic diseases is already known, having been studied as a possible risk factor for drug reactions, especially regarding their count in the platinum therapeutic cycle in which the allergic reaction occurred⁴². However, some studies carried out in this area have proven an absence of relationship or the presence of a lower number of eosinophils in patients with reactions to platinum salts when compared with non-allergic patients⁴².

Rapid drug desensitization

Rapid drug desensitization (RDD) is a procedure performed when no alternative drug in use is deemed equally effective. RDD consists in the induction of temporary unresponsiveness to drug antigens,

which allows patients to be treated with medications to which they have previously presented HSRs⁴³. RDD enables the full therapeutic doses to be reached without major side effects in a relatively short period of time⁴⁴. Several desensitization protocols have been published and used for patients with platinum drug HSRs, but most widely accepted desensitization protocols are the 8-step and 12-step, with a duration of 5.8 hours to 8 hours^{23,45,46}. The choice of a specific RDD protocol is based on the risk stratification, according to clinical history and skin test results⁴⁷. Various desensitization protocols for taxanes have been studied with the Brigham and Women's Hospital/Dana-Farber Cancer Institute, the 3-bag, 12-step protocol being the most studied as well as having an excellent safety record^{33,48}. Regarding the PLD desensitization protocol, data are limited, but the most used protocol is the same as that used for taxanes, consisting of 3 bags and 12 steps⁴⁸.

The aim of chemotherapy desensitization is to maintain a temporary tolerance to the chemotherapeutic drug involved in the patient's reaction, which is essential for effective treatment and to achieve the best possible quality of life.

The objective of our study was to describe the experience in rapid drug desensitization to antineoplastic drugs in gynaecological cancers in an Allergy and Clinical Immunology Department of a tertiary hospital.

MATERIALS AND METHODS

Study design

The authors performed a retrospective, descriptive and inferential review of patients with gynaecological cancer with a history of HSRs to chemotherapy agents who were submitted to desensitization protocols.

Enrolment took place in a tertiary hospital over a period of five years, between June 2015 and June 2020. Patients were included if they had a histologically confirmed diagnosis of gynaecological cancer – ovarian, endometrial or breast, with subtype classification according to WHO guidelines^{49,50} – associated with confirmed HSRs to chemotherapy drugs (defined by European Academy of Allergy and Clinical Immunology – EAACI - guidelines⁵¹), and who were submitted to RDD. Patients were also required to be ≥ 18 years of age and able to provide written informed consent before each desensitization.

This paper was written considering the ethical and legal principles and in accordance with the recommendations of the Declaration of Helsinki of the World Medical Association. The anonymity of all the participants of this work was guaranteed.

Subjects

Patients included were those referred to the Allergy and Clinical Immunology Department by the Gynaecology Department, with immediate-type HSRs to chemotherapy drugs and an absence of possible alternatives, and who were eligible for allergy diagnostic work-up and RDD. Patients with delayed reactions (> 24 hours) were excluded, such as drug-induced fever and exfoliative skin reactions as multiform erythema, Stevens-Johnson syndrome or toxic epidermal necrolysis. Type II and III reactions (Gell and Coombs) were also excluded.

Immediate HSRs were classified according to Brown's grading system⁵² as:

- Mild (grade I), corresponding to symptoms limited to the skin or involving a single organ/system;
- Moderate (grade II), corresponding to symptoms involving at least two organs/systems without a significant drop in blood pressure or in oxygen saturation;
- Severe (grade III), corresponding to symptoms involving at least two organs/systems and a significant drop in blood pressure or in oxygen saturation.

Organs/systems signs and symptoms of HSRs were defined as mucocutaneous (flushing, pruritus, urticaria, angioedema), respiratory (nasal symptoms, dyspnoea, wheezing, oxygen desaturation, bronchospasm, throat or chest tightness), cardiovascular (chest pain, tachycardia, lipothymia, syncope, and hypotension), gastrointestinal (nausea, vomiting, diarrhoea, and abdominal pain) and other symptoms (altered state of consciousness, headache, paraesthesia, pain).

Disease characteristics and outcomes

Patients were characterized according to demographic data, history of atopy, age at diagnosis of gynaecological cancer, histological subtype of cancer, staging, distant metastases at diagnosis, drug and therapeutic cycle involved in HSR, time interval between cycles, Brown's grading system (BGS)⁵² of HSR, drug chosen for RDD, number of therapeutic cycles in RDD, complications of RDD, the therapeutic success of RDD and mortality.

Assessment of allergy diagnosis

Each patient was evaluated with a detailed clinical history. Personal and family history of atopy were also considered.

All patients underwent skin tests for the suspected chemotherapeutic agent and latex at least 4 weeks after the initial reaction, according to The European Network for Drug Allergy/EACI recommendations⁵¹, with the exception of a single case of anthracycline reaction, where RDD was based only on clinical history due to the absence of standardization skin test concentration. Skin prick tests (SPT) were performed with undiluted agents – carboplatin (10 mg/mL), cisplatin (1 mg/mL)⁵³, paclitaxel (6 mg/mL) and docetaxel (1 mg/mL)⁵⁴. When SPT were negative, intradermal tests (IDs) were performed with a 1/10 dilution and additional dilution in cases with moderate and severe reaction (grade II and III⁵²). Immediate readings were performed at 15-20 minutes for SPT and IDs⁵¹. A weal of ≥ 3 mm in diameter for SPT or an increase in diameter of the initial ID of ≥ 3 mm were defined as a positive result, when observed a negative response to control solution (0.9% saline) and a positive response to histamine (10 mg/mL)⁵¹.

Desensitization Protocol

A 12-step protocol, described by Castells et al.⁴³ was implemented, with three dilutions of the target drug dose, containing 1/100, 1/10, and 1/1, respectively diluted in 250 mL of 0.9% saline solution.

All desensitization procedures were conducted on an inpatient regimen and were performed using premedication: clemastine 2 mg, intravenously; ranitidine 50mg, intravenously, and montelukast 10mg, *per os*, maintaining the premedication proposed by oncology according to the drug or the protocol used. Based on our experience and adapted from the literature, our RDD protocols include premedication administration 30 minutes before starting the procedure, with the exception of montelukast, which was administered in 2 steps: 12 h and 30 minutes before the procedure⁵⁵.

Angiotensin-converting enzyme inhibitors and beta-adrenergic blockers were retained for 24 hours before desensitization.

The treatment of adverse drug reactions depended on the severity: mild reactions were treated with cetirizine (10 mg administered *per os*); and moderate-severe / recurrent reactions were treated with clemastine (2 mg intravenously or intramuscularly), ranitidine (50 mg administered intravenously), and methylprednisolone sodium succinate (1-2 mg/kg administered intravenously). Bronchospasm was also treated with inhaled beta2 agonists (salbutamol or ipratropium bromide). In anaphylactic reactions, epinephrine (0.01 mg/kg intramuscular at the dilution of 1 mg/mL) was administered, corresponding, in our sample, to 1 case. ...

Upon resolution, infusion was continued at the current step, or at a previous step, depending on the severity of the reaction⁵⁶.

Statistical analysis

Statistical analysis was performed using SPSS Statistics version 24.0®. Descriptive statistics were analysed as mean and standard deviation for the variables with normal distribution, and median and interquartile range for variables without normal distribution.

RESULTS

Demographic and clinical characteristics

Twenty-two women with HSRs to chemotherapy agents were submitted to RDD, corresponding to 107 RDD procedures (mean 4.9 ± 4.5 procedures per patient). The mean age of the study cohort at the time of the first desensitization was 56.5 ± 14.3 years, ranging from 22 to 77 years old. Obesity (defined as body mass index $> 30 \text{ kg/m}^2$) was observed in 31.8% ($n = 7$), and history of atopy was confirmed in 27.2% ($n = 6$) patients: confirmed drug allergy history (nonsteroidal anti-inflammatory drugs) in $n = 3$ patients; allergic asthma and rhinitis in $n = 2$ patients and food allergy in $n = 1$. One third ($n = 2$) of the patients with a positive history of atopic disease had also a history of family atopy (allergic asthma or penicillin allergy).

Patient characteristics are summarized in Table I.

Cancer diagnosis

Regarding diagnosis, the mean age of cancer diagnosis was 51.5 ± 12.8 years, ranging from 22 to 69 years old. Most of the patients (77.3%, $n = 17$) had advanced disease (stage III or IV) at the time of diagnosis. The types and subtypes of primary cancer are summarized in Table II.

When retrospective data were collected, half of the patients, corresponding to $n = 11$, had already died due to disease progression. Of this group of patients, only one had a disease-free survival interval of more than one year. Considering patients diagnosed until 2015 (40.9%, $n = 9$), the 5-year survival rate was 55.6% ($n = 5$ of total $n = 9$).

Only 1 patient presented a BRCA (1) pathogenic mutation: a high-grade serous ovarian cancer and cisplatin HSR (patient number 16). Another patient presented a BRCA (2) variant of undetermined

significance (VUS), this one with a low-grade serous ovarian cancer and carboplatin HSR (patient number 3); these two patients presented different severity of HSRs (grade III in patient number 16 and grade I in patient number 3).

Hypersensitivity reactions and desensitization

These data are summarized in Table I and time intervals between lines of treatment are shown in Fig. 1, by patient and drug. Clinical manifestations of HSRs are illustrated in Fig. 2.

Platinum compounds: Most patients (81.8%, n = 18) presented HSRs to platinum salts: 88.9% (n = 16 of total n = 18) to carboplatin and 11.1% (n = 2 of total n = 18) to cisplatin. Regarding comorbidities, one third of the patients (n = 6 of the total n = 18) were obese and 22.2% (n = 4 of the total n = 18) had atopy.

According to BGS⁵², HSRs were characterized as grade I in 27.8% (n = 5 of total n = 18), grade II in 5.6% (n = 1 of total n = 18) and grade III in 66.7% (n = 12 of total n = 18). The first episode of HSR to platinum occurred at a median 13.0 cycles (minimum 5 cycles, maximum 19 cycles). Almost all patients (94.4%, n = 17 of total n = 18) experienced the HSR in a number of cycles ≥ 7 . The median platinum dose in the HSR cycle was 527.2 mg $\pm$ 161.2 mg, corresponding in 22.2% (n = 4 of total n = 18) to a dose $\geq$ 650 mg. Median blood eosinophil count before the administration of the HSR cycle was 98.3 cells/ μ l (minimum 0 cells/ μ l, maximum 300 cells/ μ l).

In patients diagnosed with ovarian cancer, the median time interval between the HSR and previous chemotherapy cycle was 10.7 months (minimum 2 months, maximum 23 months), and in 1 patient with ovarian cancer (patient number 15) platinum HSR occurred during the first group of cycles (5th cycle).

In patients diagnosed with endometrial cancer, the median time interval between the HSR and previous chemotherapy cycle was 49.0 months (minimum 8 months, maximum 144 months). In 1 patient with endometrial cancer (patient number 5) platinum HSR occurred during the first group of cycles cycle (8th cycle).

In 50.0% (n = 9 of total n = 18) of platinum chemotherapy HSRs, patients were under treatment with placlitaxel (skin tests confirmed platinum hypersensitivity).

Skin prick tests (SPT) with platinum compounds were positive in 38.9% of the patients (n = 7 of total n = 18), all to carboplatin (n = 4 grade III and n = 3 grade I). In all patients with positive SPT, IDs were not performed due to a significant risk of HSRs associated to the procedure. ID tests were positive in 55.5%

(n = 10 of total n = 18), n = 7 carboplatin and n = 2 cisplatin (n = 1 grade I; n = 2 grade II; n = 6 grade III). Evidence of skin test cross reactivity had been presented in 4 patients (n = 2 cisplatin, n = 2 carboplatin).

RDD was performed in all patients with the respective drug involved in the HSR, after workup through skin tests (Table I). The median number of RDD cycles was 3.5 cycles (minimum 1 cycle; maximum 24 cycles). Complications during RDD occurred in one third of the patients (n = 6 of total n = 18), almost all grade I reactions, namely pruritus, facial flush and urticaria. In one case (patient number 14, Table I), a severe type III reaction occurred, corresponding to anaphylactic shock during infusion of the eleventh step (third bag – highest concentration). In this case, intramuscular epinephrine, intramuscular clemastine, intravenous methylprednisolone and inhaled beta2 agonists were required. This patient had a type III reaction as inaugural HSR and positive SPT for carboplatin. The following desensitization protocol was adjusted to 15 steps, with only a type I reaction registered.

All patients completed the proposed chemotherapy desensitization protocol.

Taxanes: This was the second most frequent group of chemotherapy drugs that resulted in HSRs and RDD in our sample, corresponding to a total of 13.6% (n = 3) of patients (n = 1 to docetaxel, n = 1 to nab-paclitaxel and n = 1 to paclitaxel). The three patients were initially diagnosed with advanced breast cancer by 2015, resulting in a 5-year survival rate of 100.0%. Regarding comorbidities, two patients presented atopy and one patient was obese.

HSRs in this group occurred at an early stage of the chemotherapy regimen (minimum 2, maximum 3 cycles), and all patients had a grade III HSR.

Considering the patient with HSR to docetaxel, SPT were positive for ID 1: 10. The patients with paclitaxel and nab-paclitaxel HSRs had negative SPT for the respective drug.

The median number of RDD cycles was 4.0 (minimum 3 cycles, maximum 5 cycles) and none of the patients experienced complications during the RDD cycles.

All patients completed the proposed chemotherapy desensitization protocol.

Anthracyclines: Only one patient suffered from HSR (patient number 22, Table II) to PLD and underwent RDD. The patient had a diagnosis of non-metastatic breast cancer and presented no other diseases/comorbidities. HSR occurred in the 3rd cycle and was characterized as severe (grade III). No skin tests were performed. The patient underwent 5 cycles of RDD without complications, and has a current disease-free survival of 3 years.

DISCUSSION

In this study we report the experience of our hospital in 107 successful RDD performed in 27 patients who experienced immediate type HSRs to platinum compounds, taxanes, and anthracyclines. Only one patient experienced a severe complication (HSR grade III) during the first 12-step RDD, which was subsequently changed to a 15-step protocol with no complications.

It is well established that any chemotherapy agent can cause HSRs; however platinum and taxanes are the most common agents involved in HSRs and our results are in accordance with this⁵⁷. Most of our patients presented HSRs to platinum agents, and this is also partly justified by the wide use of this group in the first line of treatment of solid tumours in adults, especially for ovarian cancer.

The difference in the median time interval between the HSR and previous chemotherapy cycle in ovarian and endometrial cancer is related to the fact that there is a higher rate of relapse in the former.

In taxanes, the HSRs occurred despite Gynecology-Oncology premedication protocol, that includes: dexamethasone 10 mg and H1 and H2 antihistamines (clemastine 2 mg, ranitidine 50 mg), in the cases of paclitaxel and nab-paclitaxel⁵⁸; dexamethasone 8 mg (on the day before, the day of the treatment and the day after), in the case of docetaxel^{58,59}.

The patients selected for desensitization were those who had immediate HSRs and, therefore, the mechanism likely to be implied is based on IgE-induced sensitization, although skin tests did not confirm this in all patients, as in other published series⁶⁰. In our study, the patients selected for RDD were those with a clinical history compatible with immediate HSRs and positive SPT; and in patients with negative SPT, only those diagnosed with a more severe immediate HSRs - grade III.

Premedication for platinum includes antiemetic drugs and dexamethasone, and there is no premedication prescribed in the case of PLD⁵⁸.

Most patients in the three types of cancer had an advanced stage of the disease at the time of diagnosis, which generally requires higher doses of chemotherapy, a greater number of cycles and consequently increased chances of HSRs, and these are well established risk factors for HSRs to platinum compounds³³.

Taking into account previous investigations in which it was reported that a drug allergy history correlated with predictive risk of chemotherapy allergy^{33,61}, especially with platinum compounds, our

sample showed a low prevalence, not only regarding previous drug allergy history but also other atopic diseases, when compared to other results in the literature⁵. The presence of obesity has been associated with severe manifestations and fatal outcomes in anaphylaxis^{62,63}. In our sample, obesity was also present in a significant number of patients, not only in the platinum group, but also for taxanes, considering that almost half of these patients presented severe grade III HSRs. These data highlight obesity as a possible predictor of chemotherapy HSRs, although further studies are needed with a larger sample size.

The association of paclitaxel with platinum chemotherapy schemes improved overall survival in patients with recurrent platinum-sensitive ovarian cancer⁵. Our work has also shown that this association was very prevalent, corroborating that the combination of these drugs is considered a risk factor²⁷.

Although pathogenic mutations in BRCA 1/2 appear to increase the risk of HSRs to carboplatin infusion²⁴, our population showed a low prevalence of this mutation which was confirmed in only one woman with a cisplatin HSR. The other woman with VUS BRCA 2 mutation had a carboplatin HSR. These patients also presented heterogeneity in HSR severity, with the pathogenic variant associated with a higher-grade reaction (III).

The relationship between the presence of eosinophils and allergic diseases is already known, and has been studied as a possible risk factor in drug HSRs, especially regarding their count in the specific platinum therapeutic cycle in which the allergic reaction occurred⁶⁴. However, some studies carried out in this area have proven an absence of relationship or even the presence of a lower number of eosinophils in patients with platinum reactions⁴², as shown in our data.

In the platinum compounds HSR cases, almost the entire sample (n = 17, total n = 18) presented HSRs after ≥ 7 cycles of chemotherapy, which is in keeping with the number of cycles being considered a risk factor for allergic reactions³³. The same is not true for the other groups of drugs studied, which is also in agreement with the literature^{17,34}.

The positive skin tests did not correlate with the severity of the initial reaction, as there were cases in which the tests were positive and the HSR was mild (grade I) and cases in which the tests were negative and the HSRs were severe (grade III). Although platinum skin tests are recommended and negative test results are associated with a lower risk of anaphylaxis^{46,65}, all patients in our sample with negative skin tests had severe type III reactions, so RDD was performed in accordance to the risk assessed via clinical history. Even considering that platinum skin tests are recommended and validated, and are a

useful complementary diagnostic tool, this must always be associated with a complete and exhaustive clinical history to assess the risk of a future desensitization procedure.

Skin tests for paclitaxel showed negative results in all tested cases, which is in line with data presented in literature, corroborating that the predictive value has not yet been demonstrated⁶⁶.

The high mortality rate of our sample (50.0 %) is justified by advanced oncological disease at the date of the first HSR to chemotherapy. The same may justify the fact that, in the case of platinum salts, in which a higher dose is associated with an increased risk of HSRs, the vast majority of patients had been submitted to multiple treatment lines.

CONCLUSIONS

In all presented cases, rapid drug desensitization successfully allowed the reintroduction of antineoplastic drugs in patients with a previous history of immediate hypersensitivity reaction. Of all patients included, only one had a serious complication (anaphylaxis) during the course of the desensitization protocol, and it was necessary to adjust the protocol from 12 to 15 steps in the following cycles.

A joint protocol between the departments of gynaecology and allergy and clinical immunology allows the patients to benefit from better clinical guidance, resulting in the conclusion of the proposed chemotherapy in cases of HSRs.

Our work demonstrated the safety and effectiveness of these protocols, highlighting the advantages of gaining experience in this procedure.

REFERENCES

1. Colombo, P. *et al.* ESMO-ESGO consensus conference recommendations on ovarian cancer: Pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. *Ann. Oncol.* **30**, 672–705 (2019).
2. Prat, J. & Committee, F. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. *Int. J. Gynecol. Obstet.* **124**, 1–5 (2014).

3. Dinkelspiel, H. E. *et al.* Long-term mortality among women with epithelial ovarian cancer. *Gynecol. Oncol.* **138**, 421–428 (2015).
4. Lavigne, K. *et al.* A randomized trial of prophylactic extended carboplatin infusion to reduce hypersensitivity reactions in recurrent ovarian cancer. *Int J Gynecol Cancer.* **28**, 1176–1182 (2019).
5. Tai, Y. H. *et al.* Risk factors of hypersensitivity to carboplatin in patients with gynecologic malignancies. *Front. Pharmacol.* **8**, 1–8 (2017).
6. Global Cancer Observatory (Globocan). *Publ.* 2018. <https://gco.iarc.fr/>.
7. Colombo, N. *et al.* ESMO-ESGO-ESTRO consensus conference on endometrial cancer: Diagnosis, treatment and follow-up. *Ann. Oncol.* **27**, 16–41 (2016).
8. <https://www.cancer.gov/>, P. 2020. NIH - National Cancer Institute. .
9. Kurman, R. J., Carcangiu, M., Herrington, C. & Young, R. World Health Organization Classification of Tumours of Female Reproductive Organs. IARC. *Publ. online* 2014.
10. Pecorelli, S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. *Int. J. Gynaecol. Obstet.* **105**, 103–104 (2008).
11. Querleu, D. *et al.* Prise en charge primaire des cancers de l'endomètre: recommandations SFOG-CNGOF. *Gynecol. Obstet. Fertil. Senol.* **45**, 715–725 (2017).
12. NIH - National Cancer Institute. *Publ.* 2020. <https://www.cancer.gov/>
13. de Boer, S. M. *et al.* Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial. *Lancet Oncol.* **20**, 1273–1285 (2019).
14. Cardoso, F. *et al.* Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann. Oncol.* **30**, 1194–1220 (2019).
15. Jensen-Jarolim, E. *et al.* AllergoOncology – the impact of allergy in oncology: EAACI position paper. *Allergy Eur. J. Allergy Clin. Immunol.* **72**, 866–887 (2017).
16. Cernadas, J. R. *et al.* General considerations on rapid desensitization for drug hypersensitivity - A consensus statement. *Allergy Eur. J. Allergy Clin. Immunol.* **65**, 1357–1366 (2010).

17. Syrigou, E. *et al.* Acute hypersensitivity reactions to chemotherapy agents: An overview. *Inflamm. Allergy - Drug Targets* **9**, 206–213 (2010).
18. Scherer, K. *et al.* Desensitization in delayed drug hypersensitivity reactions - An EAACI position paper of the Drug Allergy Interest Group. *Allergy Eur. J. Allergy Clin. Immunol.* **68**, 844–852 (2013).
19. Demoly, P. *et al.* International Consensus on drug allergy. *Allergy Eur. J. Allergy Clin. Immunol.* **69**, 420–437 (2014).
20. Castells, M. Drug hypersensitivity and anaphylaxis in cancer and chronic inflammatory diseases: The role of desensitizations. *Front. Immunol.* **8**, 1–11 (2017).
21. Li, Q. *et al.* Outpatient rapid 4-step desensitization for gynecologic oncology patients with mild to low-risk, moderate hypersensitivity reactions to carboplatin/cisplatin. *Gynecol. Oncol.* **135**, 90–94 (2014).
22. Chung, S. J. *et al.* A new non-dilution rapid desensitization protocol successfully applied to all-grade platinum hypersensitivity. *Cancer Chemother. Pharmacol.* **82**, 777–785 (2018).
23. Hesterberg, P. E. *et al.* Risk stratification for desensitization of patients with carboplatin hypersensitivity: Clinical presentation and management. *J. Allergy Clin. Immunol.* **123**, 1262–1267.e1 (2009).
24. Otani, I. M., Wong, J. & Banerji, A. Platinum Chemotherapy Hypersensitivity: Prevalence and Management. *Immunol. Allergy Clin. North Am.* **37**, 663–677 (2017).
25. Abe, A., Ikawa, H. & Ikawa, S. Desensitization treatment with cisplatin after carboplatin hypersensitivity reaction in gynecologic cancer. *J. Med. Investig.* **57**, 163–167 (2010).
26. Rogers, B. B. *et al.* Oxaliplatin: Detection and management of hypersensitivity reactions. *Clin. J. Oncol. Nurs.* **23**, 68–75 (2019).
27. Miyamoto, S., Okada, R. & Ando, K. Platinum hypersensitivity and desensitization. *Jpn. J. Clin. Oncol.* **45**, 795–804 (2015).
28. Castells, M. C. Anaphylaxis to chemotherapy and monoclonal antibodies. *Immunol. Allergy Clin. North Am.* **35**, 335–348 (2015).

29. Saunders, M. P. *et al.* Short report: Hypersensitivity reactions to cisplatin and carboplatin - a report on six cases. *Ann. Oncol.* **3**, 574–576 (1992).
30. Mezzano, V., Giavina-Bianchi, P., Picard, M., Caiado, J. & Castells, M. Drug desensitization in the management of hypersensitivity reactions to monoclonal antibodies and chemotherapy. *BioDrugs* **28**, 133–144 (2014).
31. Parel, M. *et al.* Hypersensitivity to oxaliplatin: Clinical features and risk factors. *PMC Pharmacol. Toxicol.* **15**, 2–7 (2014).
32. Callahan, M. B. *et al.* Use of cisplatin without desensitization after carboplatin hypersensitivity reaction in epithelial ovarian and primary peritoneal cancer. *Am. J. Obstet. Gynecol.* **197**, 199.e1-199.e5 (2007).
33. Picard, M., Matulonis, U. A. & Castells, M. Chemotherapy hypersensitivity reactions in ovarian cancer. *J. Natl. Compr. Canc. Netw.* **12**, 389–402 (2014).
34. Picard, M. Management of Hypersensitivity Reactions to Taxanes. *Immunol. Allergy Clin. North Am.* **37**, 679–693 (2017).
35. Giavina-Bianchi, P., Patil, S. U. & Banerji, A. Immediate Hypersensitivity Reaction to Chemotherapeutic Agents. *J. Allergy Clin. Immunol. Pract.* **5**, 593–599 (2017).
36. Picard, M. & Castells, M. C. Revisiting Hypersensitivity Reactions to Taxanes: A Comprehensive Review. *Clin. Rev. Allergy Immunol.* **49**, 177–191 (2015).
37. Bonamichi-Santos, R. & Castells, M. Diagnoses and Management of Drug Hypersensitivity and Anaphylaxis in Cancer and Chronic Inflammatory Diseases: Reactions to Taxanes and Monoclonal Antibodies. *Clin. Rev. Allergy Immunol.* **54**, 375–385 (2018).
38. Chanan-Khan, A. *et al.* Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil®): Possible role in hypersensitivity reactions. *Ann. Oncol.* **14**, 1430–1437 (2003).
39. Goff, F. *et al.* Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: Analysis from the GCG CALYPSO relapsing ovarian cancer trial. *Gynecol. Oncol.* **122**, 226–232 (2011).
40. Aoyama, T. *et al.* Is there any predictor for hypersensitivity reactions in gynecologic cancer

- patients treated with paclitaxel-based therapy? *Cancer Chemother. Pharmacol.* **80**, 65–69 (2017).
41. Sendo, T. *et al.* Incidence and risk factors for paclitaxel hypersensitivity during ovarian cancer chemotherapy. *Cancer Chemother. Pharmacol.* **56**, 91–96 (2005).
 42. Makrilia, N., Syrigou, E., Kaklamanos, I., Manolopoulos, L. & Saif, M. W. Hypersensitivity reactions associated with platinum antineoplastic agents: A systematic review. *Met. Based. Drugs* **2010**, (2010).
 43. Castells, M. Rapid Desensitization for Hypersensitivity Reactions to Medications. *Immunol. Allergy Clin. North Am.* **29**, 585–606 (2009).
 44. Castells, M. Rapid desensitization for hypersensitivity reactions to chemotherapy agents. *Curr. Opin. Allergy Clin. Immunol.* **6**, 271–277 (2006).
 45. Lee, C. W., Matulonis, U. A. & Castells, M. C. Carboplatin hypersensitivity: A 6-h 12-step protocol effective in 35 desensitizations in patients with gynecological malignancies and mast cell/IgE-mediated reactions. *Gynecol. Oncol.* **15**, 370–376 (2004).
 46. Castells, M. C. *et al.* Hypersensitivity reactions to chemotherapy: Outcomes and safety of rapid desensitization in 413 cases. *J. Allergy Clin. Immunol.* **122**, 574–580 (2008).
 47. Patil, S. U. *et al.* A protocol for risk stratification of patients with carboplatin-induced hypersensitivity reactions. *J. Allergy Clin. Immunol.* **129**, 443–447 (2012).
 48. Castells Dr., M. Drug desensitization in oncology: Chemotherapy agents and monoclonal antibodies. *Drug Hypersensitivity* 413–425 (2007). doi:10.1159/000104218
 49. Kurman, R., Carcangiu, M., Herrington, C. & Young, R. *World Health Organization Classification of Tumours of Female Reproductive Organs. IARC. 4TH EDITION.* (2014).
 50. Hoon Tan, C. *et al.* The 2019 WHO classification of tumours of the breast. *Histopathology* (2020). doi:10.1111/his.14091
 51. Borkow, K. *et al.* Skin test concentrations for systemically administered drugs - An ENDA/EAACI Drug Allergy Interest Group position paper. *Allergy Eur. J. Allergy Clin. Immunol.* **68**, 702–712 (2013).

52. Brown, S. G. A. Clinical features and severity grading of anaphylaxis. *J. Allergy Clin. Immunol.* **114**, 371–376 (2004).
53. Brockow, K. *et al.* Skin test concentrations for systemically administered drugs - An ENDA/EAACI Drug Allergy Interest Group position paper. *Allergy Eur. J. Allergy Clin. Immunol.* **68**, 702–712 (2013).
54. Pagani, M. *et al.* Role of Skin Tests in the Diagnosis of Immediate Hypersensitivity Reactions to Taxanes: Results of a Multicenter Study. *J. Allergy Clin. Immunol. Pract.* **7**, 990–997 (2019).
55. Castells Guitart, M. C. Rapid drug desensitization for hypersensitivity reactions to chemotherapy and monoclonal antibodies in the 21st century. *J. Investig. Allergol. Clin. Immunol.* **24**, 72–79 (2014).
56. Burches, E., Pérez-Fidalgo, J.-A., Ferriols, F., González-Barrallo, I. & Cervantes, A. A logarithmic rapid desensitization protocol: initial experience in carboplatin hypersensitivity reactions. *J. Cancer Metastasis Treat.* **2019**, (2019).
57. Pagani, M. The Complex Clinical Picture of Presumably Allergic Side Effects to Cytostatic Drugs: Symptoms, Pathomechanism, Recognition, and Desensitization. *Med. Clin. North Am.* **94**, 835–852 (2010).
58. eviQ and Cancer Institute. Available at: <https://www.eviq.org.au/pages/about-us>.
59. Picard, M. *et al.* Risk stratification and skin testing to guide re-exposure in taxane-induced hypersensitivity reactions. *J. Allergy Clin. Immunol.* **137**, 1154–1164.e12 (2016).
60. Caiado, J., Rodrigues, T., Pedro, E., Costa, L. & Barbosa, M. P. Dessensibilização a fármacos em oncologia: Experiência de um Serviço de Imunoalergologia. *Rev. Port. Imunoalergologia* **17**, 57–74 (2009).
61. Libra, M. *et al.* Cisplatin may be a valid alternative approach in ovarian carcinoma with carboplatin hypersensitivity. Report of three cases. *Tumori* **89**, 311–313 (2003).
62. Turner, P. J. *et al.* Fatal Anaphylaxis: Mortality Rate and Risk Factors. *J. Allergy Clin. Immunol. Pract.* **5**, 1169–1178 (2017).
63. Coutinho, I. A. *et al.* Anaphylaxis in an emergency department: A retrospective 10-year study in a tertiary hospital. *Eur. Ann. Allergy Clin. Immunol.* **52**, 23–34 (2020).

64. Cetean, S. *et al.* Hypersensitivity reactions to platinum derivatives: Findings of new predictive markers. *J. B.U.ON.* **20**, 1617–1623 (2015).
65. Leguy-Seguin, V. *et al.* Diagnostic and predictive value of skin testing in platinum salt hypersensitivity. *J. Allergy Clin. Immunol.* **119**, 726–730 (2007).
66. Lagopoulos, V. & Gigi, E. Anaphylactic and anaphylactoid reactions during the regenerative period. *Hippokratia* **15**, 138–140 (2011).

CONFLICT OF INTEREST

The authors have no conflicts of interest.